Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2009 年 2 月 5 日 8:20-8:50 B 棟8階 カンファレンス室.

Slides:



Advertisements
Similar presentations
Lifestyle Modifications for Cardiovascular Prevention: The Mediterranean Diet, Fish, Oils and other Supplements: should we recommend them?
Advertisements

Obesity – a 2014 Overview Tim Greenaway PhD, FRACP Director Clinical Endocrinology Royal Hobart Hospital.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Journal Club 埼玉医科大学 総合医療センター 内分泌・糖尿病内科 Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University 松田 昌文 Matsuda, Masafumi.
Introductions Name address Favorite type of food Least favorite food Magazine you read most often All-time favorite movie Concert/performance you’d.
Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
An Automated Internet Behavioral Weight-Loss Program by Physician Referral: A Randomized Controlled Trial Featured Article: J. Graham Thomas, Tricia M.
Diet Efficacy in Obesity Gita Majdi. Outline: Obesity Diet in obesity management Types of diet Comparisons of diets.
The impact of dairy products on anthropometric and cardiometabolic indicators-A sub-study of Dietary Intervention Randomized Controlled Trial (Direct-Dairy)
Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年7月 24 日 8:20-8:50 B 棟8階 カンファレンス室.
Individualizing Targets and Tactics for High- Risk Patients With Type 2 Diabetes Practical lessons from ACCORD and other cardiovascular trials Featured.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年9月 25 日 8:20-8:50 B 棟8階 カンファレンス室.
Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年8月 30 日 8:20-8:50 B 棟8階 カンファレンス室.
Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年6月 14 日 8:20-8:50 B 棟8階 カンファレンス室.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年 12 月6日 8:20-8:50 B 棟8階 カンファレンス室.
Metabolic Effects of Bariatric Surgery
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2009 年 2 月 12 日 8:20-8:50 B 棟8階 カンファレンス室.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年7月 31 日 8:20-8:50 B 棟8階 カンファレンス室.
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355: Steven E. Kahn,
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年5月 22 日 8:20-8:50 B 棟8階 カンファレンス室.
Lars Sjöström et al N Engl J Med 2004; 351: Characteristics of the Subjects at the Time of Matching and at the Time of the Inclusion Examination.
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年 11 月 1 日 8:20-8:50 B 棟8階 カンファレンス室.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
Journal Club 埼玉医科大学 総合医療センター 内分泌・糖尿病内科 Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University 松田 昌文 Matsuda, Masafumi.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年1月 10 日 8:20-8:50 B 棟8階 カンファレンス室.
The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:
An initiative of South Asian Federation of Endocrine Societies (SAFES)
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年9月6日 8:20-8:50 B 棟8階 カンファレンス室.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年5月1日 8:20-8:50 B 棟8階 カンファレンス室.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2006 年 12 月 14 日 8:20-8:50 B 棟8階 カンファレンス室.
Azithromycin for the Secondary Prevention of Coronary Events J. Thomas Grayston, M.D., Richard A. Kronmal, Ph.D., Lisa A. Jackson, M.D., Alfred F. Parisi,
Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:
Fat or Low-fat? Anwar T. Merchant ScD, MPH, DMD Department of Epidemiology and Biostatistics.
Iris Shai, R.D., Ph.D., Dan Schwarzfuchs, M.D., Yaakov Henkin, M.D., Danit R. Shahar, R.D., Ph.D.,,etc The Dietary Intervention Randomized Controlled Trial.
Journal Club Julie Shah, MD Milton S Hershey Medical Center Penn State University.
Journal Club Julie Shah, MD Milton S Hershey Medical Center Penn State University.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
R1 강민혜 / prof. 전숙. Introduction Patients with type 2 diabetes have a greatly increased risk of cardiovascular events. The morbidity and mortality related.
1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.
Philip R. Schauer, M.D., Deepak L. Bhatt, M.D., M.P.H., John P. Kirwan, Ph.D., Kathy Wolski, M.P.H., Stacy A. Brethauer, M.D., Sankar D. Navaneethan, M.D.,
R1. 이정미 / prof. 이상열. INTRODUCTION Type 2 diabetes is a major risk factor for cardiovascular disease The presence of both type 2 diabetes and.
Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.
Christopher P. Cannon, M. D. , Eugene Braunwald, M. D. , Carolyn H
The SPRINT Research Group
Recent Breakthroughs in Cardiovascular Outcomes Trials in T2DM
Career choice for Chinese medical graduate: Safety Physician
The IDEAL Study Reference
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
Timothy A. Brighton, M. B. , B. S. , John W. Eikelboom, M. B. , B. S
SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,
OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,
Potential mechanisms whereby statins may reduce the risk of stroke
Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,
Characteristics of the Patients at Baseline*
Baseline Characteristics of the Study Participants
Baseline Characteristics of the Patients – Part I
Volume 71, Issue 2, Pages (August 2019)
Presentation transcript:

Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2009 年 2 月 5 日 8:20-8:50 B 棟8階 カンファレンス室 Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med Jan 8;360(2): Epub 2008 Dec 17. Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, Golan R, Fraser D, Bolotin A, Vardi H, Tangi-Rozental O, Zuk-Ramot R, Sarusi B, Brickner D, Schwartz Z, Sheiner E, Marko R, Katorza E, Thiery J, Fiedler GM, Blüher M, Stumvoll M, Stampfer MJ; Dietary Intervention Randomized Controlled Trial (DIRECT) Group. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med Jul 17;359(3):

Original Article Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes William Duckworth, M.D., Carlos Abraira, M.D., Thomas Moritz, M.S., Domenic Reda, Ph.D., Nicholas Emanuele, M.D., Peter D. Reaven, M.D., Franklin J. Zieve, M.D., Ph.D., Jennifer Marks, M.D., Stephen N. Davis, M.D., Rodney Hayward, M.D., Stuart R. Warren, J.D., Pharm.D., Steven Goldman, M.D., Madeline McCarren, Ph.D., M.P.H., Mary Ellen Vitek, William G. Henderson, Ph.D., Grant D. Huang, M.P.H., Ph.D., for the VADT Investigators N Engl J Med Volume 360(2): January 8, 2009

Study Overview In this study, 1791 military veterans with poorly controlled type 2 diabetes were randomly assigned to receive either standard or intensive glucose control Other cardiovascular risk factors were treated uniformly The glycated hemoglobin goal was an absolute reduction of 1.5 percentage points in the intensive- therapy group There was no significant difference between the two groups for the rates of major cardiovascular events, death, or microvascular complications

Duckworth W et al. N Engl J Med 2009;360: Enrollment and Outcomes

Characteristics of the Patients at Baseline and Follow-up Duckworth W et al. N Engl J Med 2009;360:

Changes in Median Glycated Hemoglobin Levels from Baseline through 78 Months Duckworth W et al. N Engl J Med 2009;360:

Kaplan-Meier Curves for the Time until the First Occurrence of a Primary or Secondary Outcome Duckworth W et al. N Engl J Med 2009;360:

Hypoglycemic Episodes Duckworth W et al. N Engl J Med 2009;360:

Microvascular Outcomes Duckworth W et al. N Engl J Med 2009;360:

Conclusion Intensive glucose control in patients with poorly controlled type 2 diabetes had no significant effect on the rates of major cardiovascular events, death, or microvascular complications

Myocardial Infarction Mannucci E et al: NMCD 2009 in press

Stroke Mannucci E et al: NMCD 2009 in press

Original Article Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat Diet Iris Shai, R.D., Ph.D., Dan Schwarzfuchs, M.D., Yaakov Henkin, M.D., Danit R. Shahar, R.D., Ph.D., Shula Witkow, R.D., M.P.H., Ilana Greenberg, R.D., M.P.H., Rachel Golan, R.D., M.P.H., Drora Fraser, Ph.D., Arkady Bolotin, Ph.D., Hilel Vardi, M.Sc., Osnat Tangi-Rozental, B.A., Rachel Zuk-Ramot, R.N., Benjamin Sarusi, M.Sc., Dov Brickner, M.D., Ziva Schwartz, M.D., Einat Sheiner, M.D., Rachel Marko, M.Sc., Esther Katorza, M.Sc., Joachim Thiery, M.D., Georg Martin Fiedler, M.D., Matthias Blüher, M.D., Michael Stumvoll, M.D., Meir J. Stampfer, M.D., Dr.P.H., for the Dietary Intervention Randomized Controlled Trial (DIRECT) Group N Engl J Med Volume 359(3): July 17, 2008

Study Overview This 2-year trial, which took place in an isolated workplace that facilitated retention in the study, randomly assigned 322 moderately obese subjects to one of three diets: a low-fat, restricted-calorie diet; a Mediterranean, restricted-calorie diet; or a low-carbohydrate, non-restricted-calorie diet The results suggest that the Mediterranean and low-carbohydrate diets are effective alternatives to low-fat diets and that personal preferences and metabolic considerations might inform individualized tailoring of dietary interventions

Baseline Characteristics of the Study Population Shai I et al. N Engl J Med 2008;359:

Enrollment of the Participants and Completion of the Study

Changes in Dietary Intake, Energy Expenditure, and Urinary Ketones during 2 Years of Intervention Shai I et al. N Engl J Med 2008;359:

Changes in Dietary Intake, Energy Expenditure, and Urinary Ketones during 2 Years of Intervention Shai I et al. N Engl J Med 2008;359:

Weight Changes during 2 Years According to Diet Group

Changes in Cholesterol and Triglyceride Biomarkers According to Diet Group during the Maximum Weight-Loss Phase (1 to 6 Months) and the Weight-Loss Maintenance Phase (7 to 24 Months) of the 2-Year Intervention Shai I et al. N Engl J Med 2008;359:

Changes in Biomarkers According to Diet Group and Presence or Absence of Type 2 Diabetes Shai I et al. N Engl J Med 2008;359:

Conclusion Mediterranean and low-carbohydrate diets may be effective alternatives to low-fat diets The more favorable effects on lipids (with the low-carbohydrate diet) and on glycemic control (with the Mediterranean diet) suggest that personal preferences and metabolic considerations might inform individualized tailoring of dietary interventions